NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
44 hedge funds and large institutions have $120M invested in NKGen Biotech, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
10% more capital invested
Capital invested by funds: $109M → $120M (+$11.3M)
7% more funds holding
Funds holding: 41 → 44 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$4.84M |
| 2 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
+$3.88M |
| 3 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
+$2.68M |
| 4 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$1.94M |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIH
HRS Investment Holdings
New York
|
-$2.47M |
| 2 |
NRCM
Northern Right Capital Management
Darien,
Connecticut
|
-$1.45M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$836K |
| 4 |
EAM
Exos Asset Management
New York
|
-$678K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$63.3K |
NKGN Hedge Fund Activity: Q1 2022 in Review
44 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2022, worth a combined $120M — up 10% from $109M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NKGN positions and 4 closed out — a net gain of 3 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $4.84M. The largest seller was HRS Investment Holdings, exiting entirely with an estimated $2.47M sold.
- 44 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2022, up from 41 in Q4 2021.
- Funds reported $120M of NKGen Biotech, Inc. Common Stock stock for Q1 2022, up 10% quarter-over-quarter.
- 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q1 2022 and 4 closed out, a net change of +3 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $4.84M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q1 2022 was HRS Investment Holdings, an estimated $2.47M sold.
Based on aggregated 13F filings for Q1 2022.